Determining what alterations tumor cells undergo when simultaneously inhibiting both hA1 and hA3 AR that share a sub-signal transduction will be an important step in the development of anticancer drugs targeting adenosine receptors. This evidence concerns the gene AKAP13 and neoplasm.